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Researchers develop new drugs
more suitable for liposome carriers.

Clinician and chemist forge new
approach to liposome research
Lab to Clinic

Roman Perez-Soler is an
associate professor of
medicine in the
Department of
Medical Oncology

Clinician Roman Perez-Soler, M.D., and chemist
Waldemar Priebe, Ph.D., seldom meet formally. In
their six years of researching liposomes and lipophilic
anthracyclines, their best ideas most often arise in the
hallway or over lunch in the cafeteria, a tendency that
has held true since their first meeting in 1986. Priebe
came to The University of Texas M. D. Anderson
Cancer Center hoping to apply his knowledge of
anthracycline synthesis to cancer treatment. He met
Perez-Soler as a result of their mutual interest in new
approaches to cancer therapy. Within an hour of their
first meeting, Priebe had found his niche. ''When Roman first described his work to me, I knew I could
contribute," said Priebe, an assistant professor of medicinal chemistry in the Department Medical Oncology.
"Combining the talents of a liposome expert and a
medicinal chemist was a unique but natural project. We
started to work immediately." Using their novel analogue-based approach, they have developed better liposome formulations and have created new doxorubicin
analogues that, in preclinical studies, are more effective
and less cross-resistant.

Doxorubicin diffia.tlt to encapsulate
Llposomes are fatty vesicles that form spontaneously
when phospholipids are exposed to an aqueous solution. They have been extensively explored as carriers of
different types of drugs to macrophage-rich organs,
such as the liver and spleen. At M. D. Anderson Cancer
..,.c..u.,~
~ ~ - - 1 ---,r-, mer, tiposomes containing macrophage activators,
antifungal agents, and cisplatin derivatives have been
developed and tested in clinical trials during the last few
Waldemar Priebe is an
years. However, for doxorubicin, one of the most
assistant professor of
medicinal chemistry in
effective anticancer agents, liposomal incorporation has
the Department of
proved a challenge. For over a decade, investigators
Medical Oncology
have been examining various liposomal formulations
for doxorubicin, but because it has a low affinity for
lipids, getting doxorubicin into liposomes has been
difficult, and even when the drug has been efficiently

encapsulated, the resultant liposomes have often been
unstable. Typically, once injected, the liposomal doxorubicin degrades before reaching the tumor.
"Many people thought that it would be impractical
to play with the drug to improve encapsulation, so they
chose to focus on a wide variety of liposomal formulations," said Perez-Soler, associate professor ofmedicine
in the Department of Medical Oncology. "At the time
(1986), I wasn't particularly interested in liposomal
doxorubicin, but I was interested in modifying drug
pharmacology as a way ofimproving current anticancer
therapy. When I met Waldemar, I said to myself, 'Here
is an anthracycline chemist interested in application
... ,' and then things started to click."
Their initial strategy was to solve the encapsulation
problem by focusing on better drugs rather than better
liposomes. They began by studying how chemical modifications ofanthracycline antibiotics would influence the
drug's affinity for lipids, the fatty substance that composes the liposome carrier. Using his knowledge of
anthracycline chemistry, Priebe would identify key areas
in doxorubicin's chemical structure and synthesize new
analogues accordingly; Perez-Soler would then formulate liposomes and test the formulation in animals.
When they began their research together, they had no
specific idea of which modifications would work best.
They have since studied about 40 such compounds.
Smprisingly, they have found that increasing lipophilicity
does not always increase encapsulation efficiency, as
many in me field had tlmrrght--:-'Iney have, huweve~
identified three stable preparations whose encapsulation
efficiency is over 98%. More important, one of these
drugs, liposomal annamycin, was more effective than
doxorubicin when tested in mouse tumor models.

Annamycin shows promise in preclinical trials
The drug's effect was initially studied in two cancers in
mice: L-1210 leukemia and liver metastases ofM-5076
reticulosarcoma. In L-1210 experiments, the cure rate
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using doxorubicin was 0% with two different dose
schedules, whereas with annamycin the rure rate was
50-80% (depending on the dose schedule used). In the
M-5076 experiments, annamycin showed significant
anti.tumor activity, whereas doxorubicin showed none.
Priebe and Perez-Soler's results, reported in 1990 in
Cancer Research, were only the first step. They knew
that developing effective clinical therapy would have to
address the question of drug cross-resistance. Many
tumors, though initially susceptible to a drug, eventually
become resistant not only to the drug used but also to
other drugs. This phenomenon, termed multi.drug
resistance (MDR), is being recognized as a significant
obstacle to effective chemotherapy.
Although MDRmost likely is the result ofa complex
array of biochemical mechanisms, one mechanism has
been strongly implicated: drug efllux by the P-glycopro-

focus on the amino group. They therefore synthesized a
new analogue, hydroxyrubicin, which was identical to
doxorubicin except that the amino group is replaced
with a hydroxyl group (Figure 1, p. 5).
Hydroxyrubicin experiments showed that the drug
did not encapsulate in liposomes as well as annamycin
did, so its utility in that area was limited. Nevertheless, it
proved useful in counteracting MDR In in vitro experiments comparing hydroxyrubicin with doxorubicin,
hydroxyrubicin was more effective in inhibiting growth
of resistant cell lines, had lower resistance indices in a
battery of MD R cell lines, and showed higher levels of
cellular uptake, indicating the drug was not being
effectively bound and eflluxed by P-glycoprotein. Moreover, in in vivo experiments in mice that had drugresistant P388 leukemia, the analogue showed significant anti.tumor activity and was threefold less toxic than

•

-'Combining the talents of a
liposome expert
and a medicinal chemist
was a unique but
natural project~
•
tein "pump." Drug-resistant cells typically have shown
high levels of P-glycoprotein. Presumably, P-glycoprotein binds to drugs and transports them out of the cell.
How P-glycoprotein arises is not fully known, but it is
believed that chemotherapy "selects" drug-resistant cells:
The drug kills all cells sensitive to the drug, but those few
that contain P-glycoprotein survive and proliferate. This
would explain why a drug is effective against the primary
tumor but ineffective against recurrences.
The next step: how to eliminate cross-resistance?
For Priebe and Perez-Soler, the logical next step was to
develo a Ii somal analo e
t cir
ented the Pglycoprotein pump. "The evidence implicating P-glycoprotein is highly suggestive, albeit circumstantial-a few
studies have shown that MDR can be present in the
absence of P-glycoprotein. Nevertheless, for our purposes, focusing on a way to counteract this mechanism
was a reasonable objective," Priebe said. They surmised
that drug effectiveness and P-glycoprotein binding were
controlled by different parts ofthe drug molecule. They
were not sure which part of doxorubicin participated in
binding to P-glycoprotein, but based on data in the
literature and on their own studies, they decided to
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the parent drug. Doxorubicin showed no anti.tumor
activity in this test.
Removing amino groups may reduce
cross-resistance
''We have some nice working hypotheses," Priebe
added. "Drugs that are typically thrown out of the cell
by P-glycoprotein have an amino group. By removing it
and preserving all other configurations, you can produce a non-cross-resistant compound. We've just received funding from the National Institutes offiealth to
do more studies along these lines."
"So our research is n limited to Ii osomes " PerezSoler continued. "But because liposomes are a relatively
easy drug carrier to use, we are very interested in
pursuing all their possibilities."
And it is such interest that is bringing the researchers,
prompted by the intriguing results ofthe hydroxyrubicin
experiments, back to the study ofannamycin, which also
has a hydroxyl group instead of an amino group.
"Using a study design similar to that of the
hydroxyrubicin experiments, we are finding that
continued on page 5
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Clinic will coordinate detection, screening,
and study of this familial disease.

Neurofibromatosis: a new clinic

brings new opportunities
Children with neurofibromatosis (NF), an often debilitating and sometimes fatal disease, face a difficult and
uncertain future. Not only must they cope with a disease
whose manifestations and clinical course cannot be
predicted, they also must live with a higher than average
risk of developing cancer. Moreover, because NF is a
genetic disease, they carry a 50% risk of pas.sing on the
disease to their children, and they sometimes must
watch a parent with a similar condition grow very ill.
''Whenever you identify a child with NF," said Michael
Needle, M.D., director of the Pediatric
Neurofibromatosis Clinic at The University of
Texas M. D. Anderson Cancer Center, "it is extremely
important to look at the family as a whole."
Rare genetic diseases like NF require a systematic
approach. Because the patient population is small, studies are relevant only if adequate numbers of patients are
enrolled. Moreover, the patient's family members, who
may also be at risk, must be identified, informed, and
screened. Thus, a central location for studies and disease
screening would make the provision of these functions
easier. In the fall of 1991, just such an opportunity was
created with the opening ofthe hospital's new Pediatric
Neurofibromatosis Clinic. Needle, with help from Archie
Bleyer, M.D., who heads the Division of Pediatrics, set
up the clinic at M. D. Anderson Cancer Center, bringing together a multidisciplinary team of physicians and
researchers who diagnose and treat many of the problems related to NF, including some cancers.

Disease characteristics are variable
and progressive
NF, a disorder characterized by uncontrolled benign
tumor growth, is caused by a gene mutation on chromosome 17. Only recently recognized as a number of
different but related disorders, the most commonly
identified form is NF-1, or von Recklinghausen disease.
NF-1 affects as many as 68,000 Americans, striking
equally both sexes and all races and ethnic groups. The
disease, sometimes confused with the unrelated Proteus
syndrome, or Elephant Man's disease, manifests itselfin
a variety of ways, including these three common ones:
cafe au lait spots (similar in appearance to birth marks),
neurofibromas (noncancerous tumors made up ofnerve
cells and the fibrous tissues surrounding these cells), and
Llsch nodules (small, harmless lumps in the iris of the

eye). In themselves, these three features cause few
problems. In fact, as Needle explained, during their
entire lifetime, some people will have only the cafe au lair
spots and a few small, insignificant tumors. "Some
people don't even know they have the disease," he said.
"But when you diagnose NF in a child and start talking
to the parents, sometimes the dad will just lift up his shirt
and show you his spots. Until then, he had thought they
were birthmarks." At the other extreme are those who
have more significant problems from their first year of
life, though this is uncommon. For most people who
have NF, however, the problems start small and are
generally progressive, worsening during puberty and
early adulthood.

Problems are often age related
''When we screen children in the clinic," said Needle,
''we are looking for a relatively well-defined, predictable
set of problems." These include optic nerve gliomas,
learning disabilities, scoliosis and other skeletal disorders, deafness, mental retardation, speech impediments,
early or delayed puberty, high blood pressure, and
itching. ''You can almost take it by age group," he said
of the signs and symptoms. In the youngest, below 3
years old, physicians often are simply confirming or
denying a diagnosis of NF. They look at the family
history and examine the patient for characteristic spots
or tumors. In the 3- to 5-year-olds, the major concern is
optic nerve glioma, a tumor that 10% to 15% of the
children will develop. The tumor is low grade, slow
growing, nonmetastatic, and rarely fatal, but it can take
away vision. The glioma is occasionally treated with
chemotherapy or radiotherapy. ''We are pretty good at
stopping the growth; maybe two-thirds of the time we
can arrest the tumor's progression, but we can almost
never reverse it."
The next biggest problem for this age group, according to Needle, is a 50% risk ofhaving a learning disability.
A large percentage of the children are hyperactive and
have attention-deficit disorder; a smaller group has
difficulty with visual-spatial relationships and visualspatial abstract thinking. Some seem to have difficulty
picturing things in their minds. "Another subset in the
children," said Needle, "to me probably the most
interesting of all, is a group that does very well except
when it comes to expressing things on paper." When

Treatment Update

Michael Needle is
director of the Pediatric
Neurofibromatosis
Clinic
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'-Our interventions are limited.
Current treatment is only a small
finger in the dike"
•
these children work with a computer or a video game,
they do fine, but when asked to sign their names, they
can't do it. ''We have 14-year-olds who are illiterate," he
said. "Learning disabilities are overwhelmingly our biggest problem with young adolescents."
Another very significant problem for children is the
emotional load they carry. Children already coping with
the trials of adolescence must learn to deal with lowered
self-esteem because of the various cosmetic and health
problems, anxieties over possible complications, and the
daily frustration of dealing with the disease. Moreover,
they often must watch in horror as the disease takes its
toll on another, older family member. "One of our
patients is a teenage girl whose mother died of NF, and
she's very scared," said Denise Long, RN, nurse coordinator of the clinic.

Adjustment problems are some ofthe most difficult
for children
According to Needle, the clinic currently lacks the
mechanism to look carefully at emotional problems
such as these. And while it does provide many of the
same types of services offered the hospital's cancer
patients, one particular difference stands out. Whereas
patients who have cancer come in every month or week
and are sometimes admitted for several days, patients
who have NF are seen much less frequently, sometimes
only once for an initial evaluation. The ones with
obvious problems, like the teenage girl previously mentioned, can be referred for counseling. "This child," said
Long, "is almost paralyzed by the thought that she's
going to end up like her mother-dying. And though
her tumor is benign, she does have a risk of developing
cancer." She and other children must learn to deal with
that possibility.
Needle believes that once physicians and researchers
have a better understanding of the fundamental molecular biology of NF, they can better address the
psychosocial and physiological problems associated with
the disease. "Right now," he said, ''we can recognize
them and sometimes deal with them, but we can't
reverse them, we can't cure them, and we can't prevent
them. With some understanding of the molecular biology, we may be able at least to intervene in a much more
directive fashion."
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Closing in on a gene
As a result of the new clinic, a ready source of tissue
specimens is allowing researchers to establish a number
of molecular studies related to NF. Louise Strong,
M.D ., chief of the Pediatrics Genetics section, is setting
up a genetics laboratory dedicated to the study of NF.
She said that genetics studies will help in identifying
people at risk and in arranging genetic counseling for
them. Eventually, the findings may lead to gene therapy.
Meanwhile, researchers are hoping to learn more about
the NF gene and its corresponding proteins.
The NF gene can be acquired in two ways: half the
people inherit it from a parent and half obtain it as a
result of a spontaneous mutation. Whether inherited or
acquired, the gene confers the same risk of NF for
children of these people: 50%. Vicki Huff, Ph.D., Department of Biochemistry and Molecular Biology, is
examining patterns of spontaneous mutations by comparing tissue and tumor DNA samples of patients and
relatives. She is also examining how the same gene
mutation results in such diverse effects among family
members, including malignant tumors in some but not
others. It is possible that additional spontaneous (somatic) mutations may be the cause of these diverse
effects.
Hideyuki Saya, M.D., Ph.D., and Tom Nishi, M.D.,
Ph.D., Department of Neuro-Oncology, have found
two human NF-1 DNA transcripts. These transcripts,
formed by alternative DNA splicing, produce different
NF-1 proteins that may be related to the development
of tumors in NF-1 patients. In addition, these transcripts may be important in the development of neuroectodermal brain tumors in non-NF-1 patients, said
Victor A. Levin, M.D., chairman of the department.
Two clinical trials using retinoic acid to alter the relative
amounts of these NF-1 transcripts in brain tumors are
currently under way, and a study of NF-1 patients is
being contemplated.
\

Researchers see many long-term goals for the clinic
Though the clinic is still quite new, those associated
with it are already enthusiastic about its future and
express a number of long-term goals. The hope is to
develop better ways of screening patients for major
problems, to detect those problems earlier, and to
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Liposome Research
continued from page 2

annamycin's uptake-and consequently its cytotoxicity and lack of cross-resistance-is much higher than
that of hydroxyrubicin," said Priebe. Consequently,
annamycin, because ofits high incorporation, increased
efficacy, and non-cross-resistance, may be a promising
candidate for clinical trials.
The implications of Priebe and Perez-Soler's research are far reaching; creating stable, tumor-targeted
liposomes that contain effective, non-cross-resistant
compounds would be a major advance for chemotherapy. However, they caution that attaining such a
goal is still in the future. They continue to work on
novel liposome formulations and non-cross-resistant

analogues and to study mechanisms of MDR and drug
interaction with biological membranes-a collaboration
they obviously enjoy.
''We both learn a lot from each other," said Priebe, to
which Perez-Soler readily nods. As they leave the interview and walk down the hallway, one notes that they
immediately begin a rapid-fire exchange of words. One
gets the impression that, before they reach the elevator,
yet another idea will be born.
Physicians who desire additional information may write
Roman Perez-Soler, M.D., DepartmentofMedical Oncology,
Box 80, or Waldemar Priebe, Ph.D., Department of Medical
Oncology, Box 41, The University ofTexas M. D . Anderson
Cancer Center, 1515 Holcombe Blvd., Houston, Texas
77030, or call (713) 792-6363 (Perez-Soler) or 792-3777
(Priebe) . ■
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provide improved patient care, including coordinated,
consolidated services. A common problem for NF
patients is being treated for one thing by one doctor
and for another by a different doctor. ''Very often, no
one puts the whole puzzle together," said Needle.
"Tumors, bone problems, learning disabilities-they
-------are---diet"Se--C---illlG~ll-----tr-eating- 0-n
problem may not think about the other possibilities."
Another, related, goal is closer coordination between the pediatric clinic and the Adolescent and Adult
Neurofibromatosis Clinic in the Department ofNeuroOncology. Adult patients have a different set of problems from children, explained Lesley K Newton, M.D .,
director of the clinic. The focus for adults is more on
neurological impairment and malignancies, including
neurofibrosarcomas and benign and malignant brain
tumors. The two clinics, though closely associated, are
administered independently. The hope is to eventually
find space where they can operate side by side.

Figure 1. Chemical
structure of doxorubicin
and two of its analogues,
hydroxyrubicin and
annamycin. In the
analogues, the amino
group (NH 2) is replaced
with a hydroxyl group
(OH).

ANNAMYCIN

According to Needle, the major long-term goal is
clearly prevention. "The truth is," he said, "our interventions are limited. Current treatment is only a small finger
in the dike." Needle admitted that most research is
related to diagnostic measures and has not yet translated
into intervention. "The point of the clinic," he said, "is
ootro-wait-f-OI"--ki~-0--presellt-ID--disasta-,-hutt."<r--- - - - - - - - - catch up with them early enough while their problems
are small, and ultimately, with the help of the molecular
biologists, to see how many of the problems we can
prevent altogether."
Physicians who desire additional information may write
Michael Needle, M.D., Pediatric Neurofibromatosis Clinic,
Department of Pediatrics, Box 87, or Lesley K Newton,
M.D., Adolescent and Adult Neurofibromatosis Clinic, Department of Neuro-Oncology, Box 100, The University of
Texas M. D . Anderson Cancer Center, 1515 Holcombe
Blvd., Houston, Texas 77030, or call (713) 794-5403. ■
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Computerized Network
continued from page 8
divisions of Diagnostic Radiology and Pathology and
the Section ofMelanoma/Sarcoma of the Department
of Medical Oncology. Its first goal was to create a
prototype online "teleradiology/pathology" system to
be used for multidisciplinary clinical conferences. The
planners required that the system have the ability to
capture and display radiographic and pathologic images
from anywhere in the institution and be expandable to
meet the needs of all clinical conferences held at M. D.
Anderson. The system also had to be simple to operate
by beginning computer users, require minimum software development, and be low cost; it also had to have
color capability, as pathology images must be in color to
be effective These latter requirements and superior
image quality led the development team to select the
Macintosh computer environment for their prototype.
The system, which was named MDA-Image, has
been used for over a year for four weekly clinical
conferences. Before each conference, selected radiologic and pathologic images are scanned, digitized, and
entered into the data base; at the conference, these
images are viewed on a Macintosh workstation with a
20-inch monitor. Images can be easily viewed without
the need to refer to the originals, and several images can
be viewed simultaneously and compared.
These conferences have generated a high level of
interest in the MDA-Image system among the participating medical staff. Said Mark E. Moffitt, now Director
of Diagnostic Imaging Information Services, who has
been involved in the project since its beginning, "the
real goal of the initial project was simply to develop the
capability to put these images on an electronic system.

Since then, the staff have proposed lots of different
applications."

Technology still in developmental stage
The staff's enthusiastic proposals, however, raise the
question ofthe technology's current capabilities. Several
imaging equipment vendors have expressed interest in
supporting further development; clearly, they see many
potential commercial applications in this system, such as
"turnkey" (i.e., ready-to-use) computer systems for
hospitals and diagnostic centers, interactive systems for
conferences among multiple institutions, and reference
and teaching materials, such as atlases, clinical conferences, and proceedings. There are no standards now in
place for these systems; the companies may find M. D.
Anderson's system particularly attractive because of its
unique pathology image capabilities.
Such interest by commercial vendors demonstrates
the technology's potential, but before its potential can
be realized two issues must be addressed: image quality
and hardware storage capacity. Although image quality
on the Macintosh computers is much better than average, resolution on some types ofradiology images, such
as chest radiographs and mammograms, is not as good
as the original films. (That of the pathology images is
"excellent and certainly more than adequate for diagnosis," said Alberto G. Ayala, M .D ., Department of Pathology.)
A second problem is that hardware capable ofstoring
the number of images now being generated at M. D.
Anderson is too expensive; for now only selected images, not the entire patient file, can be stored. The
availability of only selected images makes most radiologists nervous; they need to see all the images to make the
best decision. Although the eventual goal is to store all
images in the MDA-Image system, to do so now would
require six to ten storage units each the size of a small

Your last Oncolog?
To cut costs, our mailing list will be targeted to
selected medical specialties. However, regardless of your specialty, if you like MD Anderson
Oncolog and want to continue receiving it, we'd be
happy to keep sending it to you. Complete this
form and return it to the address below or call
Kevin Flynn at (713) 794-1106. Remember,
Oncolog is free.
MD Anderson Oncolog, Box 234
1515 Holcombe Blvd.
Houston, TX 77030
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"Within about 10 years, all of our
images will be stored electronically,
without need for slides or films~
•
room, according to Moffitt. John E. Grossman, Project
Director, Imaging and Software Systems, pointed out,
however, that "data storage technology is improving
quickly, and its cost is going down. It may be possible
within 10 years for all of our images to be stored
electronically, withoutneed for slides or films. Every day
there's something new; it's gotten to the point that a lot
ofthe big players-IBM, Kodak, GE-are interested in
this area." With such commercial interest, larger capacity systems should not be far behind.

Radiologic-Pathologic Institute planned
Wallace acknowledges that MDA-Image is still in a
developmental phase. He and other faculty involved in
the project are already planning new applications and
new methods of supporting project development. In
addition to the clinical conferences, "another big motivator for the project," according to Grossman, was an
anatomical atlas developed by William R Richli, M.D.,
.which brings together CT and MRI images, highquality photographs of gross specimens and thin-tissue
slices (which can be viewed from many different perspectives), and explanatory text. Richli's early version of
the atlas is now being expanded; the eventual goal is to
cover the entire human body. The faculty's most ambitious suggestion is the creation of the RadiologicPathologic Institute, a diagnostic reference and teaching center within M. D . Anderson. The institute would
both develop the image data base technologies needed
to create a universal electronic imaging system and
become a reference center for diagnostic images, offering various training materials for anatomy, radiology,
pathology, and diagnostic oncology. They also envision
that the institute would become a center for training in
those fields, by developing new teaching methods that
mcoiporate the electroruc image system.
Now that the MDA-Image system is operational for
the conferences and has at least two ongoing projects
(that is, expansion of the image data base and the
anatomical atlas), the first step toward achieving the
goals of the Radiologic-Pathologic Institute, the creation of the Texas Outreach program, has already been
taken. The Texas Outreach program, which was funded
by a grant from the Physicians Referral Service ofM. D.
Anderson, will expand the MDA-Image system's capabilities to allow sharing of electronic images with other
institutions and physicians outside M. D. Anderson. A

•
group of physicians in the Rio Grande Valley of Texas
(as yet undetermined, but perhaps connected with Pan
American University) will probably be the first outside
node in the MDA-Image network. From a workstation
placed at their location, they will be able to both send
images to and receive them from M. D. Anderson and
confer with M. D. Anderson specialists on patient
decision making. The system will also allow transmission of educational materials on diagnostic oncology.
Eventually many Texas physicians, including those in
private practices, hospitals, and industrial settings, may
be able to use this network. Expansion ofthe network is
dependent on the continuation of funding or development of other funding sources.

Educational applications of MDA-Image
Another proposed project is a series of specialized
educational CD-ROM products to be derived from the
image data base; examples are a "textbook" on gynecological oncology and the proceedings ofvarious clinical
conferences. CD-ROM not only offers illustrations far
superior to those of printed works, but also has an
interactive capability that allows the user to review the
information in the sequence he or she prefers. Ofcourse,
the CD-ROM format also offers authors the opportunity to present their knowledge and skills in a new,
dynamic way, and many are eager to respond to this
challenge.
The final plan for the MDA-Image system is its
incorporation into an expanded training program in
diagnostic oncology offered by the Radiologic-Pathologic
Institute. The institute's planners envision a true academic institute that will host physicians and researchers
from all over the world who want to take advantage of
state-of-the-art training in the field. Here at M. D.
Anderson rhey'W:tlliearn to take advantage ofcomputTI'
technologies to enhance their skills in cancer diagnosis.
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Radiology and pathology images
transmitted by computer.

Computerized network enhances
interdisdplinary patient management
Technology

Sidney Wallace is chairman
of the Department of
Diagnostic Radiology

A new computer application developed at The University ofTexas M. D. Anderson Cancer Center could
have far-reaching effects on the way radiology and
pathology images are stored, retrieved, and used. Such
images play a critical role in the diagnosis and staging of
cancer and the management of cancer patients. Sidney
ace, . ., charrman, Department o 1agnosnc
Radiology, has estimated that the divisions of Diagnostic Imaging and Pathology at M. D. Anderson Cancer
Center generate about 15,000 images each day. Several
hundred images may be generated for a single patient.
Simply keeping these images organized and accessible is
a major endeavor.
Traditionally, radiologic images have been stored in
large folders on shelves in cavernous storerooms located
far from the clinics and research areas where they are
used. Distributing, collecting, and filing these folders is
a labor- and time-intensive process. Files may become
lost, misplaced, or physically damaged. Large hospitals

and research centers that generate thousands of these
images have long sought better systems for storing and
retrieving them.
likewise, storage and retrieval of pathology images
can pose a problem, but for a different reason: each
pathologist may be responsible for or may prefer developmg or er own ca oging an · g
em. me
institutions have systems in place for shared filing systems, but retrieval may rely heavily on the memory and
knowledge of the individual who worked with the
slides. Many pathologists have recognized the need for
a shared-access system for storage and retrieval of
pathologic images.
Electronic system improves a ~ to images
Development of an electronic system that would
handle both types of images began at M. D. Anderson
in 1989. The project was undertaken jointly by the
continued on page 6

